Latham & Watkins and Mazanti-Andersen acted as legal advisors to Ascendis on the transaction, while Goodwin Procter, Kromann Reumert and Fenwick & West acted as legal...
Ascendis Pharma’s $150 Million Royalty Funding Agreement with Royalty Pharma
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
Revolution Medicines’ $345 Million Common Stock Public Offering
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
Saesa’s $1.4 Billion Acquisition of 99,42 % en Enel Transmisión Chile
Cuatrecasas advised Banco Santander S.A. and Santander Corredores de Bolsa Ltda. Carey advised Enel Chile S.A. Clifford Chance advised Milbank advised Sociedad Transmisora Metropolitana SpA Enel...
IDEAYA Biosciences’ $80 Million Common Stock Offering
Latham & Watkins represented IDEAYA, while Davis Polk advised the representatives of the several underwriters in the offering. IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced the pricing of an...
Revolution Medicines’ $230 Million Shares Offering
Latham & Watkins represented Revolution Medicines, while Davis Polk advised the underwriters in the offering. Revolution Medicines, Inc. (Nasdaq: RVMD), has announced the pricing of its underwritten...
Hasbro’s $146.3 Million Acquisition of D&D Beyond
Latham & Watkins represented Fandom in the transaction. Hasbro, Inc. (NASDAQ: HAS) has announced that it is acquiring D&D Beyond, the leading digital toolset and game companion...
National Express’s All-Share Combination With Stagecoach Group
Ashurst advised National Express on the deal. Herbert Smith Freehills advised Stagecoach Group plc. The combination will create a leading multi-modal transportation provider in the UK...
HashiCorp’s Initial Public Offering
Wilson Sonsini Goodrich & Rosati advised HashiCorp on the deal. Latham & Watkins represented the underwriters. HashiCorp®, a leader in multi-cloud infrastructure automation software, announced the pricing...
Ascendis Pharma’s $400 Million ADSs Public Offering
Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S in the transaction. Ascendis Pharma A/S (Nasdaq: ASND) has announced the pricing of its underwritten public offering of...
Aligos Therapeutics’ $83.6 Million Public Offering
Latham & Watkins LLP represented Aligos Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced...